/> September 12, Step Pharmaceuticals issued a number of consecutive announcements, the announcement behind the frequent action - the same day announced the establishment of investment in a number of subsidiaries.
The combination of the two immunotherapy combinations of Shishi Shiguibao has been approved by the FDA
Time of Update: 2021-03-03
BMS announced that the FDA has approved the PD-1 inhibitor Opdivo (nivolumab), in association with the CTLA-4 inhibitor Yeervoy (ipilimumab), to treat patients with hepatocellular carcinoma (HCC) who have previously received treatment with sorapinib.
Fda approves additional treatments for haemophilia and inhibitors of type A or B in adults and adolescents
Time of Update: 2021-03-03
the safety and effectiveity of Sevenfact was determined by data from a clinical study that assessed 27 patients with type A or b haemophilia using inhibitors, including 465 mild or moderate treatments and three severe bleeding episodes.
Sovantini was awarded two fast-track qualifications by the FDA
Time of Update: 2021-03-03
On April 17, He huang China Pharmaceutical Technology Co., Ltd. (Chi-Med, called and Huang Pharmaceuticals) announced that its oral tyrosine kinase inhibitor surufatinib has been awarded two fast-track qualifications by the FDA
New drug for cystic fibrosis (CF)! Vertex triple therapy Trikafta has been given FDA priority review to expand the population (6-11 years old)!
Time of Update: 2021-03-03
therapy Trikafta (elexacaftor/tezacaftor/ivacaftor and the scope of use of cavtor) to include CFTR gene carrying at least one F508del mutation, or CFTR gene carrying a specific mutation and based on in vitro data to respond to Trikafta treatment of 6
Lilly Tauvaid (Flortaucipir F18) is approved by the FDA
Time of Update: 2021-03-03
a way to get this important information in patients. Tauvid in two clinical studies. In study 1, 64 patients with normal and impaired end-stage cognition agreed to undergo Tauvid imaging and participate in the post-mortem
Treatment of rosacea The FDA approved the first local therapy for minotin
Time of Update: 2021-03-03
, Menlo Therapeutics announced that the U.S. FDA has approved the development of its wholly-owned subsidiary, Foamix Pharmaceuticals, to list Zilxi (1.5% minocyline, FMX103) for the treatment of adult patients with rosacea.
FDA approves Fiasp to treat diabetes in children
Time of Update: 2021-03-03
no and Nord announced today that the U.S. Food and Drug Administration has approved 100 u/ ml of Fiasp (mendon insulin injection) as an insulin option for new meals for children with diabetes.
New Alzheimer's (AD) drug! The review period of β protein antibody aducanumab was extended by 3 months by the FDA!
Time of Update: 2021-03-03
